In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Cervical Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

  • Sequencing Treatment with a PARP Inhibitor and Chemotherapy
    (Posted: 09/06/2011) - In this clinical trial, patients will be treated in 21-day cycles, with the first cycle being either intravenous carboplatin on day 1 followed by 7 days of oral olaparib or oral olaparib for 7 days followed by intravenous carboplatin on day 8. In the second cycle, the treatment assignments will be reversed.
  • New Chemotherapy Drug for Advanced Cervical Cancer
    (Posted: 04/06/2010) - In this clinical trial, women with cervical cancer that has recurred or demonstrated resistance to previous chemotherapy and that cannot be treated surgically will be treated with the drug ixabepilone.
  • Defining Optimal Therapy for Metastatic and Recurrent Cervical Cancer
    (Posted: 12/15/2009) - In this phase III trial, women with metastatic, recurrent, or persistent cervical cancer that cannot be treated with surgery and/or radiation therapy will be randomly assigned to one of four treatment groups: paclitaxel plus cisplatin, paclitaxel plus topotecan, or either of these combinations with the addition of bevacizumab.
  • Targeted Combination Therapy for Advanced Solid Tumors
    (Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined.
  • Vaccine to Prevent Cervical Cancer
    (Posted: 11/02/2004, Updated: 06/21/2005) - Researchers are testing a vaccine in women infected with HPV-16 who have cell changes associated with HPV infection (LSIL or ASCUS) to determine whether the vaccine will help develop the appropriate immune response to resolve the cell changes and clear the viral infection.